`
`———————
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`———————
`
`
`
`Regeneron Pharmaceuticals, Inc.,
`Petitioner,
`
`v.
`
`Novartis Pharma AG,
`Novartis Technology LLC,
`Novartis Pharmaceuticals Corporation,
`Patent Owner
`
`———————
`
`Case IPR2020-01318
`U.S. Patent No. 9,220,631
`———————
`PETITIONER’S REPLY REGARDING 35 U.S.C. §§ 314(a), 325(d)
`
`
`
`
`
`
`
`
`IPR2020-01318
`
`
`
`On November 17, 2020, the Board authorized Petitioner Regeneron
`
`Pharmaceuticals, Inc. (“Regeneron”) to file reply briefs in this IPR and in co-
`
`pending IPR2020-01317 addressing Patent Owner Novartis’s1 35 U.S.C. §§ 314(a)
`
`and 325(d) arguments in its Patent Owner Preliminary Responses. See Paper 14.
`
`On November 20, 2020, Regeneron requested permission from the Board to file a
`
`motion to terminate this proceeding (IPR2020-01318). The Board granted
`
`Regeneron’s request on November 24, 2020, and Regeneron’s unopposed motion
`
`to terminate is due by December 8, 2020.
`
`
`
`In light of Regeneron’s expected filing of an unopposed motion to terminate,
`
`and although it does not agree with Novartis’s §§ 314(a) and 325(d) arguments,
`
`Regeneron does not substantively respond to those arguments herein. Regeneron
`
`instead respectfully submits that the Board may preserve its resources and
`
`terminate this IPR pursuant to Regeneron’s anticipated motion without addressing
`
`the merits of either the petition or Novartis’s §§ 314(a) and 325(d) arguments. See
`
`37 C.F.R. §§ 42.71(a), 42.72.
`
`
`1 Novartis Pharma AG, Novartis Technology LLC, and Novartis Pharmaceuticals
`
`Corporation.
`
`
`
`
`
`1
`
`
`
`IPR2020-01318
`
`
`
`Regeneron represents that it is concurrently filing a Reply Brief in pending
`
`IPR2020-01317 that substantively responds to the §§ 314(a) and 325(d) arguments
`
`that Novartis raised in that proceeding.
`
`
`
`Dated: November 25, 2020
`
`
`
`
`Respectfully submitted,
`
`/Elizabeth S. Weiswasser/
`Elizabeth S. Weiswasser (Reg. No. 55,721)
`Anish R. Desai (Reg. No. 73,760)
`Natalie Kennedy (Reg. No. 68,511
`Andrew Gesior (Reg. No. 76,588)
`WEIL, GOTSHAL & MANGES LLP
`767 Fifth Avenue
`New York, NY 10153
`T: 212-310-8000
`F: 212-310-8007
`E: REGN.IPR.Service@weil.com
`
`Brian E. Ferguson (Reg. No. 36,801)
`Christopher Pepe (Reg. No. 73,851)
`WEIL, GOTSHAL & MANGES LLP
`2001 M Street NW, Suite 600
`Washington, DC 20036
`T: 202-682-7000
`F: 202-857-0940
`E: REGN.IPR.Service@weil.com
`
`
`
`
`
`2
`
`
`
`IPR2020-01318
`
`CERTIFICATE OF SERVICE
`
`I hereby certify that on November 25, 2020, copies of the foregoing
`
`
`
`
`
`PETITIONER’S REPLY REGARDING 35 U.S.C. §§ 314(a), 325(d) was served
`
`via electronic mail, as agreed to by counsel, upon the following counsel of record
`
`for the Patent Owner:
`
`Joshua Weinger (Reg. No. 73,198)
`Goodwin Procter LLP
`100 Northern Avenue
`Boston, MA 02210
`Phone: (617) 570-1000
`Fax: (617) 523-1231
`JWeinger@goodwinlaw.com
`
`
`Elizabeth J. Holland (Reg. No. 47,657)
`Linnea Cipriano (Reg. No. 67,729)
`Goodwin Procter LLP
`620 Eighth Avenue
`New York, NY 10018
`Phone: (212) 813-8800
`Fax: (212) 355-3333
`EHolland@goodwinlaw.com
`LCipriano@goodwinlaw.com
`DG-NovartisPFS@goodwinlaw.com
`
`William G. James (Reg. No. 55,931)
`Goodwin Procter LLP
`1900 N Street, N.W.
`Washington, D.C. 20036
`Phone: (202) 346-4000
`Fax: (202) 346-4444
`WJames@goodwinlaw.com
`
`
`/Brian E. Ferguson / 2
`Brian E. Ferguson (Reg. No. 36,801)
`WEIL, GOTSHAL & MANGES LLP
`2001 M Street NW, Suite 600
`Washington, DC 20036
`T: 202-682-7000
`brian.ferguson@weil.com
`
`
`
`
`
`
`
`
`
`
`
`